Nocebo-Prone Behaviour in Patients with Autoimmune Rheumatic Diseases during the COVID-19 Pandemic

George E. Fragoulis1*, Gerasimos Evangelatos1, Aikaterini Arida1, Vasiliki-Kalliopi Bournia1, Kalliopi Fragiadaki1, Anastasios Karamanakos1, Evrydiki Kravvariti1, Katerina Laskari1, Stylianos Panopoulos1, Maria Pappa1, Dimos D. Mitsikostas1, Maria G. Tektonidou1, Petros P. Sfikakis1

1First Department of Propaedeutic Internal Medicine, Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, “Laiko” General Hospital, Athens, Greece, 2First Neurology Department, Aeginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

*These authors contributed equally.

ABSTRACT

Background: The COVID-19 pandemic is associated with emotional distress and significant disruptions in health-care services. These are key players in the development of nocebo phenomena. We aimed to investigate nocebo-prone behaviour in patients with autoimmune rheumatic diseases (ARD) amid the COVID-19 pandemic-associated lockdown. Methods: Consecutive patients were telephone-interviewed during the COVID-19 pandemic in Greece. Clinical and socioeconomic characteristics (eg, level of education) were recorded. For nocebo behaviour, a four-item validated questionnaire (Q-No, cut-off score>15), was used. Results were compared with pre-COVID-19 Q-No scores collected from patients followed-up in our department. Results: Nocebo behaviour was detected in 51/500 (10.2%) individuals. In patients with nocebo behaviour, use of anti-hypertensives was less common (17.6% vs 31.8%, p=0.04), but a higher level of education was more common (58.8% vs 35.9%, p=0.002), compared with patients with Q-No score ≤15; the latter retained statistical significance in multivariate regression analysis (p=0.009, OR [95%CI]: 2.29, [1.23-4.25]). Total Q-No scores were higher in the COVID-19-period compared to the pre-COVID-19 era [median (range); 12 (4-20) vs 11 (4-20), p=0.02]. Among 78 patients with available Q-No questionnaires in the pre-COVID-19 era, 11 (14.1%) displayed nocebo behaviour, which increased to 16 (20.5%) amid the COVID-19 pandemic. Interim development of nocebo behaviour was also associated with higher educational level (p=0.049, OR: 3.65, 95%CI: 1.005-13.268). Conclusion: A considerable proportion of ARD patients manifested nocebo-prone behaviour during the COVID-19 pandemic, which was more common among those with high educational level.

Mediterr J Rheumatol 2020;31(Suppl 2):288-94
https://doi.org/10.31138/mjr.31.3.288

Article Submitted: 12 Jun 2020; Article Accepted: 30 Jun 2020; Available Online: 21 Sep 2020

Keywords: COVID-19, nocebo, autoimmune rheumatic diseases
ABBREVIATIONS
ARD: Autoimmune rheumatic diseases
COPD: Chronic obstructive pulmonary disease
COVID-19: Coronavirus disease 2019
OR: Odds ratio
Q-No: Nocebo questionnaire

INTRODUCTION
The coronavirus disease 2019 (COVID-19) pandemic has significantly affected our everyday life in many aspects. Several public health restrictive measures, such as social distancing and home isolation, were taken to impede virus spreading. Apparently, outpatient clinics, including appointments with rheumatologists, were heavily affected and therefore patient-doctor interaction has been severely disrupted. Besides, the COVID-19 pandemic is being linked with emotional distress similar to that seen in other crises. One could speculate that the psychological effects of COVID-19 pandemic could be even more pronounced in patients with autoimmune rheumatic diseases (ARD), since many of the latter are on treatment with immunosuppressives. The aforementioned factors have been characterised as key players in the nocebo effect. The latter has been described as the opposite of the placebo effect, and denotes the non-intentional negative physical symptoms in response to a medical treatment, which are not a result of pharmacologic action, but occur solely due to negative expectations on behalf of the patient. Neuro-behavioural mechanisms seem to associate with its occurrence, but are so far poorly understood. In recent years, nocebo effects have been recognized as a cause of treatment non-adherence and worse disease outcomes, which is especially relevant in patients with ARD switching to treatment with biosimilars; several studies in this field have incorporated interviews and questionnaires aiming to quantify and/or reduce nocebo-prone behaviour.

Herein, we aimed to investigate nocebo-prone behaviour in ARD patients during the COVID-19 pandemic and whether this has changed compared to the pre-COVID-19 era.

Corresponding Author:
George E. Fragoulis
Rheumatology Unit, First Department of Propaedeutic Internal Medicine
Medical School, National and Kapodistrian University of Athens
“Laiko” General Hospital, Athens, Greece
75 Mikras Asias Str, 11527 Athens, Greece
E-mail: geofragoul@yahoo.gr

MATERIALS AND METHODS

Study population and recorded parameters
Five hundred patients with various ARDs were interviewed via telephone from rheumatologists of our department during the COVID-19 pandemic period in Greece. In particular, interviews were conducted from 14/04/2020 to 22/04/2020. Patients included in this study had been followed-up for at least 6 months in the outpatient rheumatology clinics of our academic center. They were consecutively enrolled, following an alphabetical order of their surname as recorded in our files. Patients with osteoarthritis, crystal arthropathies, undifferentiated rheumatic disease, metabolic bone disease, and fibromyalgia as primary diagnosis, were excluded. The following demographic and clinical characteristics were recorded: age, sex, cohabitation (defined as living or not with a partner), region of residence (urban, semi-urban, rural), level of education (primary, secondary, higher), employment status, and disease duration. Current treatment for ARDs and for the presence of co-morbidities (hypertension, hyperlipidemia, coronary heart disease, diabetes mellitus, depression, anxiety) were also recorded.
For detection of nocebo behaviour, a validated questionnaire (Q-No), composed of four questions was performed (Supplementary Table 1). These questions referred to the period of the COVID-19 pandemic in Greece, starting on 26 February 2020 (first reported case). Nocebo behaviour was considered to be present when score of this questionnaire was above 15. In the pre-COVID-19 era, data for nocebo behaviour were collected prospectively from patients who were routinely followed-up in our outpatients’ rheumatology clinics. Also, as part of another recently published study by our group, specific questions, with predefined answer-options were asked: discontinuation or tapering of the medication being received for ARDs, possible reasons that led to drug discontinuation (including but not confined to: fear of immunosuppression and lack of resources/drug shortage), whether advice was received from a clinician or other sources, possible symptomatology compatible with COVID-19 infection, testing for COVID-19, and subjective assessment of the activity of their disease (Supplementary Table 2).
This study was conducted according to the Declaration of Helsinki and was approved by the Scientific Council of our hospital.

Statistical analysis
Patients who manifested or developed nocebo behaviour were compared to those who did not. Two-sided Fisher’s exact and Mann-Whitney tests were used to compare categorical and continuous characteristics, respectively. Wilcoxon matched paired test was used for paired samples. Binary logistic regression analysis was performed using “Positive Nocebo behaviour”as dependent variable, and sex, age, living alone, urban area of residence, unemployment, level of education, disease duration, presence of arterial hypertension, coronary heart disease, hyperlipidemia, depression, anxiety, diabetes mellitus and chronic obstructive pulmonary disease as independent variables.
disease (COPD) as independent variables. Statistical analysis was performed using SPSS 21.0 (Armonk, NY: IBM Corp, USA).

RESULTS
Nocebo behaviour during the COVID-19 pandemic
Five hundred patients with various ARDs were included. As previously described, these were: inflammatory arthritis: 52.4%, systemic lupus erythematosus: 16%, systemic sclerosis: 11%, antiphospholipid syndrome: 3.6%, Sjögren syndrome: 1.2%, polymyalgia rheumatica: 1.2%, vasculitis: 9.4%, auto-inflammatory diseases: 5.2%.

During the COVID-19 pandemic, nocebo behaviour was detected in 51/500 (10.2%) patients. Their median (range) nocebo score, 17 (16–20) was significantly higher compared to those who did not display nocebo behaviour (10 [4-17], p<0.0001). In addition, statistically significantly higher values for all individual questions of the score (all for p<0.0001) were observed in patients with nocebo behaviour (Table 1).

Associations of Nocebo behaviour and demographic, clinical and COVID-19-pandemic-related characteristics
Comparing patients who had nocebo behaviour with those who did not, we showed that the former were less frequently on anti-hypertensives (17.6% Vs 31.8%, p=0.04) and had more frequently high level of education (58.8% Vs 35.9%, p=0.002). No other differences were detected regarding demographic and clinical characteristics. COVID-19-pandemic related features, including, but not confined to, discontinuation due to fear and/or due to lack of resources, were comparable between the two groups (Table 2). Multivariate regression analysis confirmed that higher level of education was associated with nocebo behaviour (p=0.009, OR [95%CI]: 2.29, [1.23-4.25]).

Change in Nocebo behaviour during Covid-19-pandemic
Regarding the pre-COVID-19 era, data about nocebo effect were available for 78 of these 500 patients, 11 of which (14.1%) had displayed nocebo behaviour. This proportion did not differ significantly from the respective during the pandemic (p=0.324).

However, when nocebo scores were analysed as continuous variables, total Q-No scores in the 78 patients were higher in the COVID-19-period compared to the pre-COVID-19 era (median [range]; 12 [4-20] Vs 11 [4-20], p=0.02). The same was the case for question 3 (“I ask my physician for potential adverse effects of the medication he/she gives me”) of the Q-No questionnaire (median [range]; 3 [1-5] Vs 2 [1-5], p=0.02) (Table 3).

In the univariate analyses, new development of nocebo behaviour was associated with higher baseline nocebo scores (p=0.05), younger age (p=0.03), and higher education level (p=0.03). Only the latter retained its statistical significance (p=0.049, OR: 3.65, 95% confidence interval; 1.005 – 13.268) after correcting for age, sex, baseline nocebo scores and treatment with biologics or hydroxychloroquine. COVID-19-pandemic related features were comparable between patients who developed nocebo behaviour and those who did not (Table 4).

DISCUSSION
The COVID-19 pandemic, along with the measures that came with that, affected significantly our everyday life and activities. As observed in other disasters, mental health can be also affected. Although hard evidence is lacking, it is not irrational to say that this is expected to be more pronounced in patients with chronic diseases, such as ARDs. Indeed, qualitative data from a recent study showed that patients with ARDs identified emotional disturbance during the pandemic as a key issue. We hypothesised that alterations in the mental health status along with disturbances in the health-care setting would lead to nocebo-phenomena.

We showed that nocebo behaviour was observed in 10% of our cohort which was representative of the patients who are followed-up in our university rheumatology clinic. Interestingly, patients with a high educational level were more prone to nocebo behaviour, while patients

| Table 1. | Total nocebo score as well as values for each question of the Q-No questionnaire. Q-No: Questionnaire Nocebo, Q: questionnaire |
| --- | --- | --- | --- |
| Nocebo Behaviour (n=51) | Non-nocebo behaviour (n=449) | p-value |
| Q1, median (range) | 5 (2-5) | 3 (1-5) | <0.0001 |
| Q2, median (range) | 3 (1-5) | 1 (1-5) | <0.0001 |
| Q3, median (range) | 5 (3-5) | 3 (1-5) | <0.0001 |
| Q4, median (range) | 5 (3-5) | 2 (1-5) | <0.0001 |
| Sum, median (range) | 17 (16-20) | 10 (4-17) | <0.0001 |
with concomitant hypertension exhibited nocebo characteristics less frequently than those without hypertension. Regarding the former, previous data is controversial. Although it has been shown that educational status might not have any impact on nocebo effect in patients with cancer, Hoffman et al. have shown that cancer patients that have some college education experience more drug side effects than high school graduates or people that have not finished high school. Moreover, nocebo effect is more likely to be triggered during oral drug provocation tests in subjects with high education. It is possible that individuals with higher education levels might be more suspicious to drug-related adverse events. Interestingly, a recent study from China showed that people with higher education level also tended to have more psychological distress during the COVID-19 pandemic. On the other hand, there is a lack of data regarding the nocebo effect in patients under anti-hypertensives. As these drugs are effective and generally well-tolerated, one could hypothesise that they can strengthen patient’s optimism about drugs. This could indirectly decrease the nocebo effect, as optimists are less likely to follow the nocebo expectation.

Comparing the nocebo susceptibility classification before and during the COVID-19 outbreak, we found that the proportion of patients with “positive nocebo behaviour” did not differ significantly. However, an increase in the absolute number of nocebo score was noticed. This in-

| **Nocebo Behaviour (n=51)** | **Non-nocebo behaviour (n=449)** | **p-value** |
|----------------------------|---------------------------------|------------|
| **Demographics and clinical** |                                 |            |
| Age (years), mean ± SD      | 50.7 ± 14.7                     | 54.1 ± 15.4| 0.137 |
| Sex (female), n (%)         | 36 (70.6)                       | 330 (73.5) | 0.622 |
| Disease duration (years), mean ± SD | 9.7 ± 8.0                      | 10.2 ± 9.5 | 0.967 |
| Co-habitating, n (%)        | 28 (54.9)                       | 301 (67.0) | 0.09  |
| Region residence (urban), n (%) | 44 (86.3)                | 374 (83.3) | 0.693 |
| Employment, n (%)           | 49 (96.1)                       | 422 (94.0) | 0.756 |
| Higher education level, n (%) | 30 (58.8)                   | 161 (35.9) | 0.002 |
| Hypertension, n (%)         | 9 (17.6)                        | 143 (31.8) | 0.04  |
| CHD, n (%)                  | 2 (3.9)                         | 35 (7.8)   | 0.410 |
| Dyslipidaemia, n (%)        | 3 (5.8)                         | 69 (15.4)  | 0.09  |
| Osteoporosis, n (%)         | 7 (13.7)                        | 58 (12.9)  | 0.827 |
| Depression, n (%)           | 8 (15.7)                        | 76 (16.9)  | 1.000 |
| Anxiety, n (%)              | 2 (3.9)                         | 13 (2.9)   | 0.658 |
| DM, n (%)                   | 2 (3.9)                         | 41 (9.1)   | 0.293 |
| COPD, n (%)                 | 2 (3.9)                         | 9 (2.0)    | 0.311 |
| On biologics, n (%)         | 23 (45.1)                       | 224 (49.9) | 0.556 |
| On HCQ, n (%)               | 10 (19.6)                       | 124 (27.6) | 0.725 |
| **COVID-19-pandemic related features** |                                 |            |
| Drug discontinuation due to fear, n (%) | 1 (2.0)                    | 10 (2.2)   | 1.000 |
| Drug discontinuation due to lack of resources, n (%) | 1 (2.0)                     | 18 (4.0)   | 0.709 |
| Covid-19 symptoms, n (%)   | 4 (7.8)                         | 35 (7.8)   | 1.000 |
| Consultation of a clinician, n (%) | 16 (31.4)                | 108 (24.1) | 0.304 |
| Outcome (worse), n (%)      | 10 (19.6)                       | 67 (14.9)  | 0.412 |
crease was mainly attributed to the trend of increasingly asking the treating physician about the adverse events of the drugs receiving, as depicted in the question 3 of Q-No. It can be hypothesised that on the basis of a pandemic, due to the fear of immunosuppression, ARD patients refer more to their rheumatologist regarding possible drug adverse events.

We also showed that 20% of the patients developed “positive nocebo behaviour” group amid COVID-19 pandemic. This was associated with higher baseline nocebo score, younger age, and higher educational levels, with the latter retaining its statistical significance after adjustments.

We acknowledge that this study has limitations. Firstly, the nocebo behaviour was assessed differently before and during the pandemic. The Q-No questionnaire was filled by the patient itself in the outpatient clinic visit before the pandemic, but during the outbreak the questionnaire was filled by a rheumatologist after a phone call with the patient. Nevertheless, this was inevitable due to the quarantine measures. Secondly, the Q-No questionnaire has not been validated in patients with ARDs, as the clinical significance of nocebo effects in this population has been appraised only recently. To our knowledge, this is the first study to assess nocebo behaviour in ARD patients, and also in individuals in general amid the COVID-19 pandemic.

In conclusion, nocebo behaviour has been developed in a considerable proportion if ARD patients during COVID-19 pandemic. This seems to owe to patients’ concerns about drug reactions. Nocebo behaviour occurred or developed more frequently in highly-educated individuals. Rheumatologists should be aware of the negative psychological impact of the COVID-19 pandemic in ARD patients of specific characteristics. It remains to be seen whether this will be mirrored in clinical outcomes over the next months.

AUTHOR CONTRIBUTIONS
GEF and GE: study design, data analysis and interpretation, drafting the manuscript. AA, V-KB, KF, AK, EK, KL, SP, MP: data acquisition. DM: study design, data analysis and interpretation, MGT: study design, data analysis and interpretation. PPS: study inception and design, data analysis and interpretation. All authors critically revised and approved the final version of the manuscript.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

FUNDING
This study received no funding.

ETHICS APPROVAL
This study has been approved by the scientific committee of the “Laiko” general hospital. Informed consent has been obtained from all patients.

REFERENCES
1. Pfefferbaum B, North CS. Mental Health and the Covid-19 Pandemic. N Engl J Med 2020 Apr 13.
2. Kravvariti E, Kitas GD, Mitsikostas DD, Sfikakis PP. Nocebos in rheumatology: emerging concepts and their implications for clinical practice. Nat Rev Rheumatol 2018;14:727-40.
3. Tracey I. Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal effects in humans. Nat Med 2010;16:1277-83.
4. Pouillon L, Socha M, Demore B, Thilly N, Aribol V, Danese S, et al. The nocebo effect: a clinical challenge in the era of biosimilars. Expert Rev Clin Immunol 2018;14:739-49.
5. Smolen JS, Goncalves J, Quinn M, Benedetti F, Lee JY. Era of biosimilars in rheumatology: reshaping the healthcare environment. RMD Open 2019;5:e000900.
6. Kravvariti E, Kitas GD, Sfikakis PP. The Role of the Nocebo Effect in the Use of Biosimilars in Routine Rheumatology Clinical Practice. Mediterr J Rheumatol 2019;30:63-8.
7. Mitsikostas DD, Deligianni Ci. Q-No: a questionnaire to predict nocebo in outpatients seeking neurological consultation. Neurol Sci 2015;36:379-81.
8. Scherlinger M, Langlois E, Germain V, Schaeverbeke T. Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4). Semin Arthritis Rheum 2019;49:927-32.
9. Fragoulis GE, Evangelatos G, Arida A, Bounia VK, Fragiadaki K, Karamanakos A, et al. Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic. Ann Rheum Dis 2020 Published Online First: 31 May 2020.
10. Wang C, Pan R, Wan X, Tan Y, Xu L, Ho CS, et al. Immediate

Table 3. Total nocebo score and values for each question of the Q-No questionnaire. Comparison between pre-Covid-19 era and Covid-19-pandemic period. Q-No: Questionnaire Nocebo, Q: question

| Q1, median (range) | pre-Covid-19 era | Covid-19-pandemic period | p-value |
|------------------|----------------|-------------------------|---------|
| 4 (1-5)          | 4 (1-5)        | 0.212                   |
| Q2, median (range) | 2 (1-5)        | 2 (1-5)                 | 0.189   |
| Q3, median (range) | 2 (1-5)        | 3 (1-5)                 | 0.02    |
| Q4, median (range) | 3 (1-5)        | 3 (1-5)                 | 0.07    |
| Sum, median (range) | 11 (4-20)     | 12 (4-20)               | 0.02    |
NOCEBO-PRONE BEHAVIOUR IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES DURING THE COVID-19 PANDEMIC

Table 4. Comparison between patients who newly developed nocebo behaviour during Covid-19-pandemic, and those who did not. SD: standard deviation, n: number. IHD: ischemic heart disease, DM: diabetes mellitus, COPD: chronic obstructive pulmonary disease, HCQ: hydroxychloroquine.

| Demographics and co-morbidities | Development of new Nocebo behaviour (n=16) | Stable/attenuated Nocebo behaviour (n=62) | p-value |
|---------------------------------|--------------------------------------------|------------------------------------------|--------|
| Age (years), mean ± SD          | 49.7 ± 14.8                                | 57.6 ± 15.6                              | 0.03   |
| Sex (female), n (%)             | 11 (68.7)                                  | 40 (64.5)                                | 1.000  |
| Disease duration (years), mean ± SD | 12.5 ± 7.9                     | 10.1 ± 9.4                               | 0.117  |
| Co-habiting, n (%)              | 9 (56.3)                                   | 42 (67.7)                                | 0.395  |
| Region residence (urban), n (%) | 14 (87.5)                                  | 43 (69.3)                                | 0.210  |
| Employment, n (%)               | 16 (100.0)                                 | 56 (90.3)                                | 0.336  |
| Higher education level, n (%)   | 9 (56.3)                                   | 16 (25.8)                                | 0.033  |
| Noceboprevious score            | 12.4 ± 3.2                                 | 10.6 ± 4.0                               | 0.05   |
| Hypertension, n (%)             | 2 (12.5)                                   | 24 (38.7)                                | 0.07   |
| IHD, n (%)                      | 1 (6.25)                                   | 5 (8.1)                                  | 1.000  |
| Dyslipidaemia, n (%)            | 0 (0.0)                                    | 10 (16.1)                                | 0.112  |
| Osteoporosis, n (%)             | 2 (12.5)                                   | 11 (17.7)                                | 1.000  |
| Depression, n (%)               | 3 (18.8)                                   | 12 (19.3)                                | 1.000  |
| Anxiety, n (%)                  | 1 (6.25)                                   | 0 (0.0)                                  | 0.205  |
| DM, n (%)                       | 2 (12.5)                                   | 7 (11.3)                                 | 1.000  |
| COPD, n (%)                     | 0 (0.0)                                    | 1 (1.6)                                  | 1.000  |
| On Biologics, n (%)             | 10 (62.5)                                  | 37 (59.6)                                | 1.000  |
| On HCQ, n (%)                   | 2 (12.5)                                   | 9 (14.5)                                 | 1.000  |
| COVID-19-pandemic related features |                                          |                                          |        |
| Drug discontinuation due to fear, n (%) | 0 (0.0)                              | 2 (3.2)                                  | 1.000  |
| Drug discontinuation due to lack of resources, n (%) | 0 (0.0)                          | 7 (11.2)                                 | 0.334  |
| Covid-19 symptoms, n (%)        | 0 (0.0)                                    | 4 (6.4)                                  | 0.576  |
| Consultation of a clinician, n (%) | 5 (31.3)                                | 14 (22.3)                                | 0.520  |
| Outcome (worse), n (%)          | 4 (25.0)                                   | 8 (12.9)                                 | 0.254  |

Psychological Responses and Associated Factors during the Initial Stage of the 2019 Coronavirus Disease (COVID-19) Epidemic among the General Population in China. Int J Environ Res Public Health 2020;17.
11. Michaud K, Wiipfer K, Shaw Y, Simon TA, Cornish A, England BR, et al. Experiences of Patients With Rheumatic Diseases in the United States During Early Days of the COVID-19 Pandemic. ACR Open Rheumatol 2020.
12. de la Cruz M, Hui D, Parsons HA, Bruera E. Placebo and nocebo effects in randomized double-blind clinical trials of agents for the therapy for fatigue in patients with advanced cancer. Cancer 2010;116:766-74.
13. Hofman M, Morrow GR, Roscoe JA, Hickok JF, Mustian KM, Moore DF, et al. Cancer patients’ expectations of experiencing treatment-related side effects: a University of Rochester Cancer Center–Community Clinical Oncology Program study of 938 patients from community practices. Cancer 2004;101:851-1.
14. Bavbek S, Aydin Ö, Sözenm C, Yüksel S. Determinants of nocebo effect during oral drug provocation tests. Allergologia et Immunopathologia 2015;43:339-45.
15. Qiu J, Shen B, Zhao M, Wang Z, Xie B, Xu Y. A nationwide survey of psychological distress among Chinese people in the COVID-19 epidemic: implications and policy recommendations. Gen Psychiatr 2020;33:e100213.
16. Geers AL, Helfer SG, Kosbab K, Weiland PE, Landry SJ. Reconsidering the role of personality in placebo effects: dispositional optimism, situational expectations, and the placebo response. J Psychosom Res 2005;53:e100213.
17. Kern A, Kramm C, Witt CM, Barth J. The influence of personality traits on the placebo/nocebo response: A systematic review. J Psychosom Res 2020;128:109866.
**Supplementary Table 1.** Questions asked to detect nocebo behaviour. *score of 1-5 for each of the four (A-D) questions. Total score (A+B+C+D) ranges from 4-20 (7).  

| Questions                                                                 | Possible answers |
|---------------------------------------------------------------------------|------------------|
| A. I read the summary of product characteristics (SPC) before I take any medication | *1. Never, 2. Rarely, 3. Sometimes, 4. Often, 5. Always |
| B. I have stopped in the past medication, due to side effects              |                  |
| C. I ask my doctor for possible side effects of the drug I am on          |                  |
| D. Is of great importance to me, the side effects reported in the SPC     |                  |

**Supplementary Table 2.** Questions asked during the telephone survey. ^start of pandemic for Greece, is considered the 26th of February, when the first case of covid-19 was confirmed. #: patients who did not /get prescription, who could not go to the pharmacy, # discontinuation, reduction, escalating  

| Questions                                                                 | Possible answers |
|---------------------------------------------------------------------------|------------------|
| A1. Did you discontinue/ taper any of your medications received for rheumatic diseases during Covid-19 pandemic? | YES / NO         |
| If YES, did you have any reason?                                          |                  |
| 1. “scared of infections”, 2. “forgot to take my medication”, 3. “lack of resources”, 4. “respiratory infection”, 5. “adverse events or non-efficacy”, 6. “other” (free text) | |
| A2. Did you consult anyone for changing your medication YES / NO           |                  |
| If YES, whom?                                                            |                  |
| 1. Family doctor, 2. Rheumatologist, 3. Public health authorities, 4. Media, 5. Other patients/forums, 6. Relatives/friends, 7. Other (free text) | |
| B1. Did you have any of the following symptoms: cough, fever, dyspnoea, olfactory loss, diarrhoea, myalgias, severe fatigue | YES / NO         |
| B2. Test for Covid-19                                                     | Positive/Negative/Not done |
| C. How do you feel about your rheumatic disease, over the last month?     | 1. Significantly improved, 2. Mildly improved, 3. Stable, 4. Mildly deteriorated, 5. Significantly deteriorated. |

